Literature DB >> 9114393

Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes.

F Elgh1, A Lundkvist, O A Alexeyev, H Stenlund, T Avsic-Zupanc, B Hjelle, H W Lee, K J Smith, R Vainionpää, D Wiger, G Wadell, P Juto.   

Abstract

Worldwide, hantaviruses cause more than 100,000 human infections annually. Rapid and accurate methods are important both in monitoring acute infections and for epidemiological studies. We and others have shown that the amino termini of hantavirus nucleocapsid proteins (Ns) are sensitive tools for the detection of specific antibodies in hantavirus disease. Accordingly, we expressed truncated Ns (amino acids 1 to 117) in Escherichia coli from the five hantaviruses known to be pathogenic to man; Hantaan (HTN), Seoul (SEO), Dobrava (DOB), Sin Nombre (SN), and Puumala (PUU) viruses. In order to obtain pure antigens for use in an enzyme-linked immunosorbent assay (ELISA), the recombinant proteins were purified by polyhistidine-metal chelate affinity chromatography. Polyclonal animal antisera and a panel of serum specimens from hantavirus-infected individuals from Scandinavia, Slovenia, Russia, Korea, China, and the United States were used to evaluate the usefulness of the method. With both human and animal sera, it was possible to designate the antibody response into two groups: those with HTN, SEO, and DOB virus reactivity on the one hand and those with SN and PUU virus reactivity on the other. In sera from Scandinavia, European Russia, and the United States, the antibody response was directed mainly to the PUU and SN virus group. The sera from Asia reacted almost exclusively with the HTN, SEO, and DOB types of viruses. This was true for both the immunoglobulin M (IgM) and IgG antibody responses, indicating that this type of discrimination can be done during the acute phase of hantavirus infections. Both the HTN, SEO, and DOB virus and the PUU and SN virus types of antibody response patterns were found in patients from the Balkan region (Solvenia).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114393      PMCID: PMC232715          DOI: 10.1128/jcm.35.5.1122-1130.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  Detection of nephropathia epidemica (Puumala virus)-specific immunoglobulin M by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; T Kjelsson
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

2.  Hemorrhagic fever with renal syndrome in Finland: ecology and virology of nephropathia epidemica.

Authors:  M Brummer-Korvenkontio; H Henttonen; A Vaheri
Journal:  Scand J Infect Dis Suppl       Date:  1982

Review 3.  Nephropathia epidemica (hemorrhagic fever with renal syndrome) in Scandinavia.

Authors:  B Settergren
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

Review 4.  Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome.

Authors:  T M Cosgriff
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

5.  Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients.

Authors:  Y K Chu; G Jennings; A Schmaljohn; F Elgh; B Hjelle; H W Lee; S Jenison; T Ksiazek; C J Peters; P Rollin
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

6.  Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome.

Authors:  H Feldmann; A Sanchez; S Morzunov; C F Spiropoulou; P E Rollin; T G Ksiazek; C J Peters; S T Nichol
Journal:  Virus Res       Date:  1993-12       Impact factor: 3.303

7.  Cloning and sequencing of Puumala virus Sotkamo strain S and M RNA segments: evidence for strain variation in hantaviruses and expression of the nucleocapsid protein.

Authors:  O Vapalahti; H Kallio-Kokko; E M Salonen; M Brummer-Korvenkontio; A Vaheri
Journal:  J Gen Virol       Date:  1992-04       Impact factor: 3.891

8.  Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity.

Authors:  A Lundkvist; H Kallio-Kokko; K B Sjölander; H Lankinen; B Niklasson; A Vaheri; O Vapalahti
Journal:  Virology       Date:  1996-02-15       Impact factor: 3.616

9.  A major antigenic domain for the human humoral response to Puumala virus nucleocapsid protein is located at the amino-terminus.

Authors:  F Elgh; A Lundkvist; O A Alexeyev; G Wadell; P Juto
Journal:  J Virol Methods       Date:  1996-05       Impact factor: 2.014

10.  A retrospective analysis of sera collected by the Hemorrhagic Fever Commission during the Korean Conflict.

Authors:  J W LeDuc; T G Ksiazek; C A Rossi; J M Dalrymple
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

View more
  33 in total

1.  Diagnostic potential of puumala virus nucleocapsid protein expressed in Drosophila melanogaster cells.

Authors:  K Brus Sjölander; I Golovljova; A Plyusnin; A Lundkvist
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Sangassou virus, the first hantavirus isolate from Africa, displays genetic and functional properties distinct from those of other murinae-associated hantaviruses.

Authors:  Boris Klempa; Peter T Witkowski; Elena Popugaeva; Brita Auste; Lamine Koivogui; Elisabeth Fichet-Calvet; Thomas Strecker; Jan Ter Meulen; Detlev H Krüger
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 3.  The nucleocapsid protein of hantaviruses: much more than a genome-wrapping protein.

Authors:  Monika Reuter; Detlev H Krüger
Journal:  Virus Genes       Date:  2017-11-20       Impact factor: 2.332

4.  Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays based on recombinant Puumala and Dobrava hantavirus nucleocapsid proteins.

Authors:  Helga Meisel; Anne Wolbert; Ausra Razanskiene; Andreas Marg; Andris Kazaks; Kestutis Sasnauskas; Georg Pauli; Rainer Ulrich; Detlev H Krüger
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

5.  Utilization of hantavirus antibody results generated over a five-year period to develop an improved serologic algorithm for detecting acute Sin Nombre hantavirus infection.

Authors:  Harry E Prince; Xin Su; Wayne R Hogrefe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

6.  Central European Dobrava Hantavirus isolate from a striped field mouse (Apodemus agrarius).

Authors:  Boris Klempa; Michal Stanko; Milan Labuda; Rainer Ulrich; Helga Meisel; Detlev H Krüger
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

Review 7.  A global perspective on hantavirus ecology, epidemiology, and disease.

Authors:  Colleen B Jonsson; Luiz Tadeu Moraes Figueiredo; Olli Vapalahti
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

8.  Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Authors:  R L Brocato; M J Josleyn; V Wahl-Jensen; C S Schmaljohn; J W Hooper
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

9.  Indirect immunofluorescence assay for the simultaneous detection of antibodies against clinically important old and new world hantaviruses.

Authors:  Sabine Lederer; Erik Lattwein; Merle Hanke; Karen Sonnenberg; Winfried Stoecker; Åke Lundkvist; Antti Vaheri; Olli Vapalahti; Paul K S Chan; Heinz Feldmann; Daryl Dick; Jonas Schmidt-Chanasit; Paula Padula; Pablo A Vial; Raluca Panculescu-Gatej; Cornelia Ceianu; Paul Heyman; Tatjana Avšič-Županc; Matthias Niedrig
Journal:  PLoS Negl Trop Dis       Date:  2013-04-04

10.  A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Authors:  Rebecca L Brocato; Christopher D Hammerbeck; Todd M Bell; Jay B Wells; Laurie A Queen; Jay W Hooper
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.